Loading…

Hormonal and Metabolic Effects of Radiotherapy in Acromegaly: Long-Term Results in 128 Patients Followed in a Single Center

Conventional radiotherapy is usually indicated in acromegaly when surgery fails to normalize GH secretion. However, the benefits of radiotherapy are delayed. This has raised questions about the potency of this treatment for reaching the safe GH level of 2.5 μg/L and for normalizing insulin-like grow...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 2000-10, Vol.85 (10), p.3779-3785
Main Authors: Barrande, Gaëlle, Pittino-Lungo, Myriam, Coste, Joël, Ponvert, Dominique, Bertagna, Xavier, Luton, Jean Pierre, Bertherat, Jérôme
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2420-b44dd415d85cdd81aebe817f03dbc3031bcc39a375695028e6fc08c51e08f3ce3
cites
container_end_page 3785
container_issue 10
container_start_page 3779
container_title The journal of clinical endocrinology and metabolism
container_volume 85
creator Barrande, Gaëlle
Pittino-Lungo, Myriam
Coste, Joël
Ponvert, Dominique
Bertagna, Xavier
Luton, Jean Pierre
Bertherat, Jérôme
description Conventional radiotherapy is usually indicated in acromegaly when surgery fails to normalize GH secretion. However, the benefits of radiotherapy are delayed. This has raised questions about the potency of this treatment for reaching the safe GH level of 2.5 μg/L and for normalizing insulin-like growth factor I (IGF-I) levels, both of which are currently recommended as the therapeutic goal. To evaluate the long-term hormonal and metabolic effects of radiotherapy in acromegaly, a retrospective analysis was undertaken studying 128 patients followed for 11.5 ± 8.5 yr (mean ± sd) in a single center. The preradiation GH levels decreased as a function of time to 50% at 2 yr, 20% at 5 yr, and 10% at 10 yr. Basal GH levels below 2.5 μg/L were obtained in 7% of the patients at 2 yr, 35% at 5 yr, 53% at 10 yr, and 66% at 15 yr. A basal GH level below 2.5 μg/L was associated with suppression of GH below 2 μg/L during an oral glucose tolerance test and normalization of IGF-I levels in 9 of 10 patients. Preradiation GH levels was the sole factor that could predict the delay in GH fall to below 2.5 μg/L (P = 0.008). At the last follow-up, IGF-I levels were normalized in 79% of the patients (37 of 47; mean follow-up, 15.0 ± 11.3 yr). In the 32 patients presenting with diabetes mellitus, improvement of glucose tolerance was associated with lower GH levels after treatment (35 ± 78 μg/L in the group of 13 patients still presenting diabetes; 9 ± 12 μg/L in the group of 4 patients with glucose intolerance; 5 ± 8 μg/L in the 14 patients with normal glucose tolerance; P = 0.04). Ten years after termination of radiotherapy gonadotroph, thyreotroph and corticotroph deficiencies were observed in 80%, 78%, and 82% of the patients, respectively. In conclusion, conventional radiotherapy can reduce GH levels below the optimal level of 2.5 μg/L and normalize IGF-I levels in acromegaly. However, the incidence of late hypopituitarism is high, and the delay to obtain this safe GH secretory status can be long, depending on the preradiation GH level. These parameters should be considered when adjuvant therapy is needed after surgery.
doi_str_mv 10.1210/jcem.85.10.6870
format article
fullrecord <record><control><sourceid>endocrinepress_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1210_jcem_85_10_6870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1210_jcem_85_10_6870</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2420-b44dd415d85cdd81aebe817f03dbc3031bcc39a375695028e6fc08c51e08f3ce3</originalsourceid><addsrcrecordid>eNp1kMFKAzEQhoMoWKtnr3mBrclm0816K6W1QkWpFbwt2WRSt2STkmyR4subpV49DT__fMPwIXRPyYTmlDzsFXQTwScpT0VJLtCIVgXPSlqVl2hESE6zqsw_r9FNjHtCaFFwNkI_Kx8676TF0mn8Ar1svG0VXhgDqo_YG7yRuvX9FwR5OOHW4ZkKvoOdtKdHvPZul20hdHgD8WgTkBZoLvCb7FtwKS-9tf4b9FBI_N66nQU8TxWEW3RlpI1w9zfH6GO52M5X2fr16Xk-W2cqL3KSNUWhdUG5FlxpLaiEBgQtDWG6UYww2ijFKslKPq04yQVMjSJCcQpEGKaAjdHD-W56PMYApj6EtpPhVFNSD-7qwV0t-JAHd4mYnglw2qvQOjgEiLHe-2NIruK_4C9ZNHYz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Hormonal and Metabolic Effects of Radiotherapy in Acromegaly: Long-Term Results in 128 Patients Followed in a Single Center</title><source>Oxford Journals Online</source><creator>Barrande, Gaëlle ; Pittino-Lungo, Myriam ; Coste, Joël ; Ponvert, Dominique ; Bertagna, Xavier ; Luton, Jean Pierre ; Bertherat, Jérôme</creator><creatorcontrib>Barrande, Gaëlle ; Pittino-Lungo, Myriam ; Coste, Joël ; Ponvert, Dominique ; Bertagna, Xavier ; Luton, Jean Pierre ; Bertherat, Jérôme</creatorcontrib><description>Conventional radiotherapy is usually indicated in acromegaly when surgery fails to normalize GH secretion. However, the benefits of radiotherapy are delayed. This has raised questions about the potency of this treatment for reaching the safe GH level of 2.5 μg/L and for normalizing insulin-like growth factor I (IGF-I) levels, both of which are currently recommended as the therapeutic goal. To evaluate the long-term hormonal and metabolic effects of radiotherapy in acromegaly, a retrospective analysis was undertaken studying 128 patients followed for 11.5 ± 8.5 yr (mean ± sd) in a single center. The preradiation GH levels decreased as a function of time to 50% at 2 yr, 20% at 5 yr, and 10% at 10 yr. Basal GH levels below 2.5 μg/L were obtained in 7% of the patients at 2 yr, 35% at 5 yr, 53% at 10 yr, and 66% at 15 yr. A basal GH level below 2.5 μg/L was associated with suppression of GH below 2 μg/L during an oral glucose tolerance test and normalization of IGF-I levels in 9 of 10 patients. Preradiation GH levels was the sole factor that could predict the delay in GH fall to below 2.5 μg/L (P = 0.008). At the last follow-up, IGF-I levels were normalized in 79% of the patients (37 of 47; mean follow-up, 15.0 ± 11.3 yr). In the 32 patients presenting with diabetes mellitus, improvement of glucose tolerance was associated with lower GH levels after treatment (35 ± 78 μg/L in the group of 13 patients still presenting diabetes; 9 ± 12 μg/L in the group of 4 patients with glucose intolerance; 5 ± 8 μg/L in the 14 patients with normal glucose tolerance; P = 0.04). Ten years after termination of radiotherapy gonadotroph, thyreotroph and corticotroph deficiencies were observed in 80%, 78%, and 82% of the patients, respectively. In conclusion, conventional radiotherapy can reduce GH levels below the optimal level of 2.5 μg/L and normalize IGF-I levels in acromegaly. However, the incidence of late hypopituitarism is high, and the delay to obtain this safe GH secretory status can be long, depending on the preradiation GH level. These parameters should be considered when adjuvant therapy is needed after surgery.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jcem.85.10.6870</identifier><language>eng</language><publisher>Endocrine Society</publisher><ispartof>The journal of clinical endocrinology and metabolism, 2000-10, Vol.85 (10), p.3779-3785</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2420-b44dd415d85cdd81aebe817f03dbc3031bcc39a375695028e6fc08c51e08f3ce3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Barrande, Gaëlle</creatorcontrib><creatorcontrib>Pittino-Lungo, Myriam</creatorcontrib><creatorcontrib>Coste, Joël</creatorcontrib><creatorcontrib>Ponvert, Dominique</creatorcontrib><creatorcontrib>Bertagna, Xavier</creatorcontrib><creatorcontrib>Luton, Jean Pierre</creatorcontrib><creatorcontrib>Bertherat, Jérôme</creatorcontrib><title>Hormonal and Metabolic Effects of Radiotherapy in Acromegaly: Long-Term Results in 128 Patients Followed in a Single Center</title><title>The journal of clinical endocrinology and metabolism</title><description>Conventional radiotherapy is usually indicated in acromegaly when surgery fails to normalize GH secretion. However, the benefits of radiotherapy are delayed. This has raised questions about the potency of this treatment for reaching the safe GH level of 2.5 μg/L and for normalizing insulin-like growth factor I (IGF-I) levels, both of which are currently recommended as the therapeutic goal. To evaluate the long-term hormonal and metabolic effects of radiotherapy in acromegaly, a retrospective analysis was undertaken studying 128 patients followed for 11.5 ± 8.5 yr (mean ± sd) in a single center. The preradiation GH levels decreased as a function of time to 50% at 2 yr, 20% at 5 yr, and 10% at 10 yr. Basal GH levels below 2.5 μg/L were obtained in 7% of the patients at 2 yr, 35% at 5 yr, 53% at 10 yr, and 66% at 15 yr. A basal GH level below 2.5 μg/L was associated with suppression of GH below 2 μg/L during an oral glucose tolerance test and normalization of IGF-I levels in 9 of 10 patients. Preradiation GH levels was the sole factor that could predict the delay in GH fall to below 2.5 μg/L (P = 0.008). At the last follow-up, IGF-I levels were normalized in 79% of the patients (37 of 47; mean follow-up, 15.0 ± 11.3 yr). In the 32 patients presenting with diabetes mellitus, improvement of glucose tolerance was associated with lower GH levels after treatment (35 ± 78 μg/L in the group of 13 patients still presenting diabetes; 9 ± 12 μg/L in the group of 4 patients with glucose intolerance; 5 ± 8 μg/L in the 14 patients with normal glucose tolerance; P = 0.04). Ten years after termination of radiotherapy gonadotroph, thyreotroph and corticotroph deficiencies were observed in 80%, 78%, and 82% of the patients, respectively. In conclusion, conventional radiotherapy can reduce GH levels below the optimal level of 2.5 μg/L and normalize IGF-I levels in acromegaly. However, the incidence of late hypopituitarism is high, and the delay to obtain this safe GH secretory status can be long, depending on the preradiation GH level. These parameters should be considered when adjuvant therapy is needed after surgery.</description><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNp1kMFKAzEQhoMoWKtnr3mBrclm0816K6W1QkWpFbwt2WRSt2STkmyR4subpV49DT__fMPwIXRPyYTmlDzsFXQTwScpT0VJLtCIVgXPSlqVl2hESE6zqsw_r9FNjHtCaFFwNkI_Kx8676TF0mn8Ar1svG0VXhgDqo_YG7yRuvX9FwR5OOHW4ZkKvoOdtKdHvPZul20hdHgD8WgTkBZoLvCb7FtwKS-9tf4b9FBI_N66nQU8TxWEW3RlpI1w9zfH6GO52M5X2fr16Xk-W2cqL3KSNUWhdUG5FlxpLaiEBgQtDWG6UYww2ijFKslKPq04yQVMjSJCcQpEGKaAjdHD-W56PMYApj6EtpPhVFNSD-7qwV0t-JAHd4mYnglw2qvQOjgEiLHe-2NIruK_4C9ZNHYz</recordid><startdate>200010</startdate><enddate>200010</enddate><creator>Barrande, Gaëlle</creator><creator>Pittino-Lungo, Myriam</creator><creator>Coste, Joël</creator><creator>Ponvert, Dominique</creator><creator>Bertagna, Xavier</creator><creator>Luton, Jean Pierre</creator><creator>Bertherat, Jérôme</creator><general>Endocrine Society</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200010</creationdate><title>Hormonal and Metabolic Effects of Radiotherapy in Acromegaly: Long-Term Results in 128 Patients Followed in a Single Center</title><author>Barrande, Gaëlle ; Pittino-Lungo, Myriam ; Coste, Joël ; Ponvert, Dominique ; Bertagna, Xavier ; Luton, Jean Pierre ; Bertherat, Jérôme</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2420-b44dd415d85cdd81aebe817f03dbc3031bcc39a375695028e6fc08c51e08f3ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barrande, Gaëlle</creatorcontrib><creatorcontrib>Pittino-Lungo, Myriam</creatorcontrib><creatorcontrib>Coste, Joël</creatorcontrib><creatorcontrib>Ponvert, Dominique</creatorcontrib><creatorcontrib>Bertagna, Xavier</creatorcontrib><creatorcontrib>Luton, Jean Pierre</creatorcontrib><creatorcontrib>Bertherat, Jérôme</creatorcontrib><collection>CrossRef</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barrande, Gaëlle</au><au>Pittino-Lungo, Myriam</au><au>Coste, Joël</au><au>Ponvert, Dominique</au><au>Bertagna, Xavier</au><au>Luton, Jean Pierre</au><au>Bertherat, Jérôme</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hormonal and Metabolic Effects of Radiotherapy in Acromegaly: Long-Term Results in 128 Patients Followed in a Single Center</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><date>2000-10</date><risdate>2000</risdate><volume>85</volume><issue>10</issue><spage>3779</spage><epage>3785</epage><pages>3779-3785</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><abstract>Conventional radiotherapy is usually indicated in acromegaly when surgery fails to normalize GH secretion. However, the benefits of radiotherapy are delayed. This has raised questions about the potency of this treatment for reaching the safe GH level of 2.5 μg/L and for normalizing insulin-like growth factor I (IGF-I) levels, both of which are currently recommended as the therapeutic goal. To evaluate the long-term hormonal and metabolic effects of radiotherapy in acromegaly, a retrospective analysis was undertaken studying 128 patients followed for 11.5 ± 8.5 yr (mean ± sd) in a single center. The preradiation GH levels decreased as a function of time to 50% at 2 yr, 20% at 5 yr, and 10% at 10 yr. Basal GH levels below 2.5 μg/L were obtained in 7% of the patients at 2 yr, 35% at 5 yr, 53% at 10 yr, and 66% at 15 yr. A basal GH level below 2.5 μg/L was associated with suppression of GH below 2 μg/L during an oral glucose tolerance test and normalization of IGF-I levels in 9 of 10 patients. Preradiation GH levels was the sole factor that could predict the delay in GH fall to below 2.5 μg/L (P = 0.008). At the last follow-up, IGF-I levels were normalized in 79% of the patients (37 of 47; mean follow-up, 15.0 ± 11.3 yr). In the 32 patients presenting with diabetes mellitus, improvement of glucose tolerance was associated with lower GH levels after treatment (35 ± 78 μg/L in the group of 13 patients still presenting diabetes; 9 ± 12 μg/L in the group of 4 patients with glucose intolerance; 5 ± 8 μg/L in the 14 patients with normal glucose tolerance; P = 0.04). Ten years after termination of radiotherapy gonadotroph, thyreotroph and corticotroph deficiencies were observed in 80%, 78%, and 82% of the patients, respectively. In conclusion, conventional radiotherapy can reduce GH levels below the optimal level of 2.5 μg/L and normalize IGF-I levels in acromegaly. However, the incidence of late hypopituitarism is high, and the delay to obtain this safe GH secretory status can be long, depending on the preradiation GH level. These parameters should be considered when adjuvant therapy is needed after surgery.</abstract><pub>Endocrine Society</pub><doi>10.1210/jcem.85.10.6870</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-972X
ispartof The journal of clinical endocrinology and metabolism, 2000-10, Vol.85 (10), p.3779-3785
issn 0021-972X
1945-7197
language eng
recordid cdi_crossref_primary_10_1210_jcem_85_10_6870
source Oxford Journals Online
title Hormonal and Metabolic Effects of Radiotherapy in Acromegaly: Long-Term Results in 128 Patients Followed in a Single Center
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A27%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-endocrinepress_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hormonal%20and%20Metabolic%20Effects%20of%20Radiotherapy%20in%20Acromegaly:%20Long-Term%20Results%20in%20128%20Patients%20Followed%20in%20a%20Single%20Center&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Barrande,%20Gae%CC%88lle&rft.date=2000-10&rft.volume=85&rft.issue=10&rft.spage=3779&rft.epage=3785&rft.pages=3779-3785&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/jcem.85.10.6870&rft_dat=%3Cendocrinepress_cross%3E10_1210_jcem_85_10_6870%3C/endocrinepress_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2420-b44dd415d85cdd81aebe817f03dbc3031bcc39a375695028e6fc08c51e08f3ce3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true